"The US Food and Drug Administration (FDA) is investigating the "rare but serious" risk for slowed or difficult breathing in children 17 and younger treated with the opioid analgesic tramadol.
"This risk may be increased in children tr"...
Clinical consequences of overdosage with OptiMARK have not been reported. Treatment of overdose is directed toward supporting vital functions and prompt institution of symptomatic therapy. OptiMARK has been shown to be dialyzable [see CLINICAL PHARMACOLOGY].
OptiMARK is contraindicated in patients with:
- chronic, severe kidney disease (glomerular filtration rate, GFR < 30 mL/min/1.73m²)
- acute kidney injury
- known hypersensitivity reactions to gadolinium, versetamide or any of the inert ingredients.
Last reviewed on RxList: 12/15/2014
Additional OptiMARK Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.